|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-3-14
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) mutations are associated with sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the relationships between the two most common types of somatic EGFR mutations, exon 19 deletions and L858R mutations, and clinical outcomes of Korean NSCLC patients after treatment with gefitinib or erlotinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1432-1335
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
137
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
687-94
|
|
pubmed:meshHeading |
pubmed-meshheading:20552223-Adult,
pubmed-meshheading:20552223-Aged,
pubmed-meshheading:20552223-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20552223-Disease-Free Survival,
pubmed-meshheading:20552223-Exons,
pubmed-meshheading:20552223-Female,
pubmed-meshheading:20552223-Genotype,
pubmed-meshheading:20552223-Humans,
pubmed-meshheading:20552223-Lung Neoplasms,
pubmed-meshheading:20552223-Male,
pubmed-meshheading:20552223-Middle Aged,
pubmed-meshheading:20552223-Mutation,
pubmed-meshheading:20552223-Protein Kinase Inhibitors,
pubmed-meshheading:20552223-Quinazolines,
pubmed-meshheading:20552223-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20552223-Salvage Therapy
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, Korea.
|
|
pubmed:publicationType |
Journal Article
|
